. Author manuscript; available in PMC: 2021 Feb 17.

Published in final edited form as: J Infect Dis. 2014 Dec 10;211(11):1800–1812. doi: 10.1093/infdis/jiu674

Table 4.

Characteristics of options to improve population immunity prior to WPV1 introduction and potential 2013 SIA strategies after the detection of the WPV1 circulation.

	Number of new infections 2013–2014	Cumulative cases in 2013–2014	Reduction in WPV1 elimination time (days)	Additional vaccine doses administered (millions) 2005–2014
	Number of new infections 2013–2014	Cumulative cases in 2013–2014	Reduction in WPV1 elimination time (days)	OPV	IPV
Reference case	7,700	0.8	Reference^*	Reference	Reference
Maintain sequential IPV/OPV schedule after 2005	8	0.001	340	4.30	0
No response	172,500	18	-	−1.02	0
Response 45 days after onset of the 1^st paralytic case	40,900	4	−310	0	0
SIA 1 month earlier	4,200	0.4	43	0	0
SIA duration of 4 days	5,700	0.6	32	0	0
SIA lasting 4 days, 1 month earlier	2,800	0.3	73	0	0
Better SIA coverage	7,600	0.8	0	0.27	0

Reference case assumes 360 days with die-out occurring February 1, 2014.

Abbreviation: IPV, inactivated polio vaccine; OPV, oral polio vaccine; SIA, supplemental immunization activity; WPV1, wild poliovirus type 1.